Extracellular vesicles in anti-tumor drug resistance:Mechanisms and therapeutic prospects
10.1016/j.jpha.2023.12.010
- Author:
Cheng HAO-YANG
1
;
Su GUANG-LIANG
;
Wu YU-XUAN
;
Chen GANG
;
Yu ZI-LI
Author Information
1. State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration,Key Laboratory of Oral Biomedicine Ministry of Education,Hubei Key Laboratory of Stomatology,School & Hospital of Stomatology,Wuhan University,Wuhan,430079,China
- Keywords:
Extracellular vesicle;
Anti-Tumor therapy;
Drug resistance;
Mechanisms;
Prospects
- From:
Journal of Pharmaceutical Analysis
2024;14(7):940-954
- CountryChina
- Language:Chinese
-
Abstract:
Drug resistance presents a significant challenge to achieving positive clinical outcomes in anti-tumor therapy.Prior research has illuminated reasons behind drug resistance,including increased drug efflux,alterations in drug targets,and abnormal activation of oncogenic pathways.However,there's a need for deeper investigation into the impact of drug-resistant cells on parental tumor cells and intricate crosstalk between tumor cells and the malignant tumor microenvironment(TME).Recent studies on extracellular vesicles(EVs)have provided valuable insights.EVs are membrane-bound particles secreted by all cells,mediating cell-to-cell communication.They contain functional cargoes like DNA,RNA,lipids,proteins,and metabolites from mother cells,delivered to other cells.Notably,EVs are increasingly recognized as regulators in the resistance to anti-cancer drugs.This review aims to summarize the mechanisms of EV-mediated anti-tumor drug resistance,covering therapeutic approaches like chemo-therapy,targeted therapy,immunotherapy and even radiotherapy.Detecting EV-based biomarkers to predict drug resistance assists in bypassing anti-tumor drug resistance.Additionally,targeted inhibition of EV biogenesis and secretion emerges as a promising approach to counter drug resistance.We highlight the importance of conducting in-depth mechanistic research on EVs,their cargoes,and functional ap-proaches specifically focusing on EV subpopulations.These efforts will significantly advance the devel-opment of strategies to overcome drug resistance in anti-tumor therapy.
